Talis Biomedical

Talis Biomedical Corp. develops and commercializes innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company was founded on June 26, 2013 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Talis Biomedical Corp. develops and commercializes innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company was founded on June 26, 2013 and is headquartered in Chicago, IL.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Talis Biomedical Corporation (“Talis” or the “Company”) (NASDAQ: TLIS) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company's February 2021 initial public offering (“IPO” or the “Offering”). Talis investors have until March 8, 2022

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Talis Biomedical Corporation (TLIS) Investors

NEW YORK--(BUSINESS WIRE)-- #Biomedical--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Talis Biomedical Corporation (“Talis Biomedical” or the “Company”) (NASDAQ: TLIS) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Talis Biomedical securities pursuant and/or traceable to the February 12, 2021 IPO. Investors

TALIS BIOMEDICAL ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Talis Biomedical Corporation and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California captioned Modrak v. Talis Biomedical Corporation, et al., (Case No. 22-cv-105) on behalf of persons and entities that purchased or otherwise acquired Talis Biomedical Corporation (“Talis” or the “Company”) (NASDAQ: TLIS) common stock pursuant and/or traceable to the registration statement and prospec

TLIS CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Lawsuit Against Talis Biomedical Corporation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Talis Biomedical Corporation (“Talis” or the “Company”) (NASDAQ: TLIS) investors concerning the Company's possible violations of the federal securities laws. On August 10, 2021, Talis reported its second quarter 2021 financial results. During the related conference call, the Company revealed that its “development timelines have been extended by delays in the launching of [Talis'] COVID-19 tes

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $TLIS #investors--The Law Offices of Frank R. Cruz Continues Its Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors

The Law Offices of Frank R. Cruz Continues Its Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Talis Biomedical Corporation (“Talis” or the “Company”) (NASDAQ: TLIS) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Talis investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit yo

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors

MENLO PARK, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that Rob Kelley, the Company's current Chief Commercial Officer, has been promoted to Chief Executive Officer and Director, effective immediately. Brian Blaser has stepped down from the positions of President, Chief Executive Officer and Director, due to personal matters.

Talis Biomedical Announces Leadership Transition

LOS ANGELES, Dec. 3, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz continues its investigation of Talis Biomedical Corporation ("Talis" or the "Company") (NASDAQ: TLIS) on behalf of investors concerning the Company's possible violations of federal securities laws.

The Law Offices of Frank R. Cruz Continues Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors

MENLO PARK, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care (the “Company”), announced that the Company's Board of Directors has granted an inducement award to Brian Blaser, the Company's newly appointed Chief Executive Officer. The inducement award was granted pursuant to the Company's 2021 Inducement Plan (the “Inducement Plan”) as an inducement material to Mr. Blaser entering into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4).

Talis Biomedical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Talis Biomedical Corporation (TLIS) CEO Kim Popovits on Q3 2021 Results - Earnings Call Transcript

Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific

Talis Biomedical Announces Third Quarter 2021 Financial Results and Business Progress

Veteran executive previously led Abbott's global diagnostics organization

Talis Biomedical Announces Appointment of Brian Blaser as President, Chief Executive Officer and Director

The stock price of Talis Biomedical Corp (NASDAQ: TLIS) increased by over 15% during intraday trading today. This is why it happened.

Talis Biomedical (TLIS) Stock: Why The Price Surged Today

The FDA has granted Emergency Use Authorization (EUA) to Talis Biomedical Corporation's (NASDAQ:TLIS) Talis One COVID-19 Test System, a nucleic acid amplification test (NAAT).  The Talis One system enables sample-to-answer molecular testing in less than 30 minutes.

Why Are Talis Shares Trading Higher Today?

Authorized for use in a variety of healthcare and congregate settings, Talis One™ enables lab-quality results without the wait to detect or rule out COVID-19 in less than 30 minutes

Talis Biomedical Granted FDA Emergency Use Authorization (EUA) for COVID-19 Molecular Point-of-Care Test to Detect SARS-CoV-2

MENLO PARK, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that it will release financial results for the third quarter after market close on Monday, November 15, 2021. Talis will host a conference call, beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss financial and operational results.

Talis Biomedical to Announce Third Quarter 2021 Financial Results on November 15, 2021

LOS ANGELES--(BUSINESS WIRE)---- $TLIS #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of Talis Biomedical Corporation (“Talis” or the “Company”) (NASDAQ: TLIS) investors concerning the Company and its officers' possible violations of the federal securities laws. If you suffered a loss on your Talis investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can subm

Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)---- $TLIS #CLASSACTION--Law Offices of Howard G. Smith continues its investigation on behalf of Talis Biomedical Corporation (“Talis” or the “Company”) (NASDAQ: TLIS) investors concerning the Company and its officers' possible violations of federal securities laws. On August 10, 2021, Talis reported its second quarter 2021 financial results. During the related conference call, the Company revealed that its “development timelines have been extended by delays in the launching of [Talis']

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Talis Biomedical Corporation (“Talis” or the “Company”) (NASDAQ: TLIS) on behalf of Talis stockholders. Our investigation concerns whether Talis has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On August 10, 2021, Talis reported its second quarter 2021 finan

TALIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Talis on Behalf of Talis Stockholders and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $TLIS #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Talis Biomedical Corporation (“Talis” or the “Company”) (NASDAQ: TLIS) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Talis investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securit

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $TLIS #investors--The Law Offices of Frank R. Cruz Announces Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors

Kim Popovits to serve as interim CEO Kim Popovits to serve as interim CEO

Talis Biomedical Announces CEO Transition

Talis Biomedical's (TLIS) CEO Brian Coe on Q2 2021 Results - Earnings Call Transcript

Talis Biomedical Announces Second Quarter 2021 Financial Results and Business Progress

Talis Biomedical Corporation (TLIS) CEO Brian Coe on Q1 2021 Results - Earnings Call Transcript

News for Talis Biomedical Stock (TLIS)